ALEC EBRAIM VAEZI
Medical Practice in Pittsburgh, PA

License number
Pennsylvania MD436838
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15232

Professional information

Alec Vaezi Photo 1

Alec Vaezi, Worcester MA

Work:
Umass Memorial Medical Center - University Campus
55 Lake Ave N, Worcester, MA 01655 UPMC Latterman Family Health Center
5200 Centre Ave, Pittsburgh, PA 15232 Eye & Ear Institute
200 Lothrop St, Pittsburgh, PA 15213


Alec E Vaezi Photo 2

Dr. Alec E Vaezi, Pittsburgh PA - MD (Doctor of Medicine)

Specialties:
Ear, Nose, and Throat
Address:
5200 Centre Ave STE 211, Pittsburgh 15232
(412) 621-0123 (Phone)
UNIVERSITY OF MASSACHUSETTS MEMORIAL MEDICAL CENTER
55 Lake Ave N, Worcester 01655
(508) 334-3206 (Phone), (508) 856-4668 (Fax)
Certifications:
Otolaryngology, 2010
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
5200 Centre Ave STE 211, Pittsburgh 15232
UNIVERSITY OF MASSACHUSETTS MEMORIAL MEDICAL CENTER
55 Lake Ave N, Worcester 01655
Upmc Mercy
1400 Locust St, Pittsburgh 15219
UPMC Passavant - Cranberry
1 Saint Francis Way, Cranberry Twp 16066
Upmc Shadyside
5230 Center Ave, Pittsburgh 15232


Alec Vaezi Photo 3

Use Of Choline-Phosphate Cytidylyltransferase-Alpha (Cct-Alpha) As A Biomarker For Cancer Prognosis

US Patent:
2013020, Aug 8, 2013
Filed:
Feb 4, 2013
Appl. No.:
13/758780
Inventors:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA, US
Nikhil Ramchandra Bhagwat - Pittsburgh PA, US
Alec E. Vaezi - Pittsburgh PA, US
International Classification:
G01N 33/68
US Classification:
424 946, 435 74, 435 613, 435 612, 506 9, 435 611
Abstract:
It has previously been demonstrated that positive 8F1 immunohistochemistry is an indicator of a poor cancer prognosis and poor response to chemotherapy. The 8F1 antibody was generated by immunization against ERCC1, a DNA repair protein, but recognizes a second, previously unidentified protein in cells and tissues. Disclosed herein is the finding that in addition to ERCC1, the 8F1 antibody recognizes the choline phosphate cytidylyltransferase-α (CCTα) protein. Thus, provided herein is a method of determining the prognosis of a patient with cancer by specifically detecting expression of CCTα in a sample obtained from the subject. Also provided is a method of predicting the response of a cancer patient to treatment with a genotoxic therapy by specifically detecting expression of CCTα in a sample obtained from the subject.